Biotech | May 09, 2022
SCG Cell Therapy announces HSA clinical trial approval of TCR-T cell therapy for liver cancer
SCG101 is an autologous T-cell receptor (TCR) T-cell therapy for liver cancer
SCG101 is an autologous T-cell receptor (TCR) T-cell therapy for liver cancer
CLNK is a biotechnology research and development company that utilizes umbilical cord blood as the raw material to develop innovative, allogeneic, off-the-shelf, cell based therapeutic products
Under the agreement, Porton Advanced will provide services to accelerate the development, production and registration of breakthrough cell therapies currently being developed by Sinorda Biomedicine
Yescarta is First CAR T-cell therapy to receive NCCN treatment guideline category 1 recommendation --
Allogeneic discogenic cell therapy was well tolerated and produced clinically meaningful, statistically significant improvements in low back pain, function, and quality of life by 12 weeks following intradiscal injection
The first patient dosed with VX-880 demonstrated restoration of insulin production and achieved C-peptide of 560 pmol/L in response to Mixed Meal Tolerance Test (MMTT) at Day 90 visit
Fresh Phase 1b/2a data highlight the strength of the iberdomide + daratumumab + dexamethasone combination in transplant-deferred or ineligible NDMM
Clinical trials found that 77% of patients went into remission after receiving obe-cel
The European Commission’s green light marks Breyanzi’s fourth indication in Europe and extends access to patients across all EU and EEA countries
Cobenfy generated $43 million in third-quarter sales, up from $35 million in the second quarter
Subscribe To Our Newsletter & Stay Updated
